Sobi gains distribution rights for Megace(R), Monopril(R), Cefzil(R); and Duricef(R); from PharmaSwiss

Sobi gains distribution rights for Megace(R), Monopril(R), Cefzil(R); and 
Duricef(R); from PharmaSwiss 
STOCKHOLM, SWEDEN -- (Marketwire) -- 02/13/13 --  Sobi (STO: Sobi)
announced that it has entered into a distribution agreement with
PharmaSwiss to market the products
Megace(R), Monopril(R), Cefzil(R)
and Duricef(R) approved for the treatment of indications within the
oncology, cardio-vascular and anti-infective therapy areas. Under the
terms of the agreement, Sobi will have distribution rights
in
Ireland, United Kingdom, France, Italy, Germany, Spain, Finland,
Sweden, Denmark, Norway, Austria, Belgium, Liechtenstein, Netherlands,
Portugal, and
Luxembourg. All products are approved within the Sobi
territory, where sales in 2012 were approximately SEK 120 million
(EUR 14 million).  Sobi expects to initiate distribution for the
portfolio by the end of the first quarter 2013. 
Anders Edvell, Vice President and Head of Partner Products at Sobi,
said: "We
have built a unique European platform with Partner Products
to support the complex clinical and reimbursement requirements of
niche and specialty products.  We are delighted to be able to provide
patients and physicians with
this portfolio of important treatment
options, and to welcome PharmaSwiss as a new partner." 
About Megace(R) (megestrol):  Megace is a progestogen hormone drug is
indicated
for the treatment of certain hormone-dependent neoplasms
such as breast cancer. 
About Monopril(R) (fosinopril):  Monopril is an angiotensin
converting enzyme
(ACE) inhibitor indicated for treatment of
hypertension and congestive heart
failure. 
About Cefzil(R) (cefprozil):  Cefzil is a broad-spectrum
cephalosporin antibiotic
indicated for the treatment of mild to
moderate infections. 
About Duricef(R) (cefadroxil):  Duricef is a cephalosporin antibiotic
indicated
for the treatment of urinary tract infections, skin
infections, pharyngitis and/or tonsillitis, where the infections are
caused by susceptible strains of
designated microorganisms. 
About Sobi Partner Products 
Sobi Partner Products (SPP) is a business unit within Sobi which
offers a unique
commercial platform for partners with niche and
specialty products. SPP provides
extensive knowledge and local
experience through our direct presence across EU,
Eastern
 Europe,
Russia, Middle East and North Africa.  We apply an
integrated
commercial, medical, and market access approach to
products which address important unmet needs, working from named
patient use (NPU) programs through to reimbursement and
commercialization, primarily in the Centre of Expertise setting. The
key SPP therapeutic areas are Oncology, Hematology, Infectious
Diseases, and Emergency Medicines & Antidotes. 
About Sobi 
Sobi is an international specialty healthcare company dedicated to
rare diseases. Our mission is to develop and deliver innovative
therapies and services to improve the lives of patients. The product
portfolio is primarily
focused on inflammation and genetic diseases,
with three late stage biological
development projects within
hemophilia and neonatology. We also market more than
40 specialty and
rare disease products for partner companies. Sobi is a pioneer
in
biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2011, Sobi had total revenues of SEK
1.9 billion (EUR 214 M) and about 500 employees. The share (STO: SOBI)
is listed on NASDAQ OMX
Stockholm. More information is available at
www.sobi.com. 
The information above has been published pursuant to the Swedish
Securities Market Act and/or the Financial Instruments Trading Act.
The information was
released for public distribution on February 13,
2013 at 08:30 a.m. CET. 
Sobi Press Release on February 13, 2013, in PDF format:
http://hugin.info/134557/R/1677552/547139.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: 
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE 
[HUG#1677552] 
Contact at Sobi
Anders Edvell
Vice President and Head of Partner Products
Phone: +46 8 697 2000 
Jorgen Winroth
Vice President Investor Relations
Phone: +46 8 6973427
 
 
Press spacebar to pause and continue. Press esc to stop.